5:35 PM
 | 
Dec 07, 2012
 |  BC Extra  |  Company News

G-BA: Orphan Signifor has 'marginal' additional benefit

Germany's Federal Joint Committee (G-BA) issued a final assessment that said Signifor pasireotide from Novartis AG (NYSE:NVS; SIX:NOVN) provides a "marginal" degree of additional benefit for patients with Cushing's disease for whom surgery is not an...

Read the full 166 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >